BiotechTube

SCH 56592 + SCH 56592 + SCH 56592 + SCH 56592 + Terbinafine + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Onychomycosis

Conditions

Onychomycosis

Trial Timeline

Jun 1, 2007 → Dec 1, 2008

NCT ID
NCT00491764

About SCH 56592 + SCH 56592 + SCH 56592 + SCH 56592 + Terbinafine + Placebo

SCH 56592 + SCH 56592 + SCH 56592 + SCH 56592 + Terbinafine + Placebo is a phase 2 stage product being developed by Merck for Onychomycosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00491764. Target conditions include Onychomycosis.

What happened to similar drugs?

2 of 10 similar drugs in Onychomycosis were approved

Approved (2) Terminated (1) Active (7)
🔄terbinafine + Placebo + terbinafine + PlaceboNovartisPhase 3
🔄terbinafine hydrogen chloride + amorolfine nail lacquerNovartisPhase 3
🔄terbinafine + Placebo + terbinafine + PlaceboNovartisPhase 3
🔄AN2690 Topical Solution, 5% + Solution VehiclePfizerPhase 3
✅Tavaborole 5% Topical SolutionPfizerApproved
🔄AN2690 Topical Solution, 5% + Solution VehiclePfizerPhase 3
🔄Itraconazole 100mg capsules + Itraconazole 200mg tablets + Placebo tabletsGSK plcPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00491764Phase 2Completed

Competing Products

20 competing products in Onychomycosis

See all competitors
ProductCompanyStageHype Score
NVXT Solution + Vehicle of test productSun PharmaceuticalPhase 2
35
NVXT topical + Placebo (Vehicle) TopicalSun PharmaceuticalPhase 2
35
terbinafine + Placebo + terbinafine + PlaceboNovartisPhase 3
40
terbinafine hydrogen chloride + amorolfine nail lacquerNovartisPhase 3
40
terbinafine + Placebo + terbinafine + PlaceboNovartisPhase 3
40
AN2690PfizerPhase 2
35
AN2690, 2.5% + AN2690, 5% + AN2690, 7.5% + VehiclePfizerPhase 2
35
AN2690 Solution, 5.0% + AN2690 Solution, 7.5%PfizerPhase 2
35
AN2690 Topical Solution, 5% + Solution VehiclePfizerPhase 3
40
AN2690 + AN2690PfizerPhase 2
35
Tavaborole 5% Topical SolutionPfizerApproved
43
AN2690 Solution, 5.0%PfizerPhase 2
35
AN2690, 2.5% + AN2690, 5% + AN2690, 7.5% + AN2690 Solution VehiclePfizerPhase 2
35
AN2690PfizerPhase 2
35
AN2690 Topical Solution, 5% + Solution VehiclePfizerPhase 3
40
AN2690 + AN2690 + AN2690PfizerPhase 1
29
Albaconozole + Placebo + Albaconozole + Placebo + Albaconozole + PlaceboGSK plcPhase 1
29
Itraconazole 100mg capsules + Itraconazole 200mg tablets + Placebo tabletsGSK plcPhase 3
40
Albaconazole tablet 400mg + Albaconazole 100mg capsules, then albaconazole 400mg tabletGSK plcPhase 1
29
Albaconazole 100mg + Albaconazole 200mg + Albaconazole 400mg + Albaconazole 400mg + Placebo 400 mgGSK plcPhase 2
35